Triple

T1633921
Position Surface form Disambiguated ID Type / Status
Subject Calico LLC E35320 entity
Predicate hasResearchCollaboration P28602 FINISHED
Object AbbVie E184183 NE FINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: AbbVie | Statement: [Calico LLC, hasResearchCollaboration, AbbVie]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: AbbVie
Context triple: [Calico LLC, hasResearchCollaboration, AbbVie]
  • A. AbbVie chosen
    AbbVie is a global biopharmaceutical company known for developing and marketing innovative therapies in areas such as immunology, oncology, and neuroscience.
  • B. Pfizer
    Pfizer is a major American multinational pharmaceutical and biotechnology corporation known for developing a wide range of prescription medicines and vaccines, including one of the first widely used COVID-19 vaccines.
  • C. Abbott Laboratories
    Abbott Laboratories is a global healthcare company that develops and manufactures medical devices, diagnostics, branded generic medicines, and nutritional products.
  • D. Novartis
    Novartis is a global Swiss-based pharmaceutical company known for developing innovative medicines across a wide range of therapeutic areas.
  • E. AstraZeneca
    AstraZeneca is a global biopharmaceutical company known for researching, developing, and manufacturing prescription medicines across areas such as oncology, cardiovascular, respiratory, and immunology.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
PD Predicate disambiguation gpt-5-mini-2025-08-07 
Target predicate: hasResearchCollaboration
Context triple: [Calico LLC, hasResearchCollaboration, AbbVie]
  • A. hasResearcher
    Indicates that an entity is associated with or linked to a specific researcher responsible for work, study, or investigation related to it.
  • B. topicOfAcademicCollaboration chosen
    Indicates that the entities are partners in a shared academic research or scholarly collaboration.
  • C. conductsResearchAt
    Indicates that a subject carries out research activities at a specified institution, organization, or location.
  • D. hasResearchArea
    Indicates that an entity (such as a person, project, or organization) is associated with or focused on a particular field or area of research.
  • E. hasResearchStatus
    Indicates that an entity holds a particular stage or condition within a research process, such as planned, in progress, completed, or published.
  • F. None of above.

Provenance (4 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a886036bc081909ff5de16dbe5e8ea completed March 4, 2026, 7:20 p.m.
NER Named-entity recognition batch_69a96083e7308190abbf025fe8e43abb completed March 5, 2026, 10:52 a.m.
NED1 Entity disambiguation (via context triple) batch_69ad6099979481908e2c506323d546dd completed March 8, 2026, 11:42 a.m.
PD Predicate disambiguation batch_69a907cac610819083cafd4396b6d66c completed March 5, 2026, 4:34 a.m.
Created at: March 4, 2026, 7:28 p.m.